Published in Gene Therapy Weekly, September 8th, 1997
Bacillus Calmette-Guerin (BCG) has been used in more than 3 billion people for protection against Mycobacterium tuberculosis, with a very low incidence of serious side effects. Recently, the development of integrative and extrachromosomal expression vectors has enabled cloning and expression of foreign genes in BCG (Aldovini et al., Nature 1991;351:479-482). A variety of viral, bacterial, and parasitic antigens have been expressed successfully in BCG. In...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.